Sunshine Biopharma Delays Annual SEC Filing

Sunshine Biopharma ( (SBFM) ) has released a notification of late filing.

Sunshine Biopharma Inc. has filed a Form 12b-25 to notify investors of a delayed Form 10-K (Yearly Report) for the financial year ended December 31, 2025. The company’s annual filing is therefore not arriving on its original SEC due date, but management is formally disclosing the delay.

Management cites time constraints tied to compiling, distributing, and reviewing all the information required for the Form 10-K (Yearly Report) as the key reason for the setback. The firm notes that meeting the original deadline would have imposed undue hardship and expense, suggesting workload and resource pressure rather than a specific accounting or audit issue.

The company states that it expects to file the Form 10-K (Yearly Report) no later than fifteen calendar days after the original deadline. This timing aligns with the extension window allowed under SEC Rule 12b-25 for late annual reports and signals that the delay is meant to be short-term.

Sunshine Biopharma Inc. indicates that all other required periodic filings over the past 12 months have been submitted on time. It also does not anticipate any significant changes in operating results compared with the prior fiscal year to appear in the upcoming earnings statements, which may reassure investors watching for negative surprises.

Because the company is not flagging major shifts in financial performance, the notification primarily serves as a procedural update rather than a warning of deteriorating fundamentals. Nonetheless, forward-looking expectations about timing and financial results remain subject to revision once the full Form 10-K (Yearly Report) is filed and reviewed by the market.

The company emphasizes its intention to remain in compliance by completing the Form 10-K (Yearly Report) within the allowed extension period. The notification is signed by Chief Executive Officer Dr. Steve N. Slilaty on March 31, 2026, underscoring executive-level responsibility for the filing process and the disclosure to shareholders.

The most recent analyst rating on (SBFM) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Sunshine Biopharma stock, see the SBFM Stock Forecast page.

Spark’s Take on SBFM Stock

According to Spark, TipRanks’ AI Analyst, SBFM is a Neutral.

Sunshine Biopharma’s overall stock score is primarily impacted by its financial performance and valuation. The company faces significant profitability and cash flow challenges, reflected in a low financial performance score. The technical analysis indicates a bearish trend, while the negative P/E ratio and lack of dividend yield result in a poor valuation score. These factors collectively contribute to a low overall stock score.

To see Spark’s full report on SBFM stock, click here.

More about Sunshine Biopharma

Average Trading Volume: 37,409

Technical Sentiment Signal: Strong Sell

Current Market Cap: $4.96M

See more data about SBFM stock on TipRanks’ Stock Analysis page.